Table 3.
Axial inflammatory symptoms, extra-articular manifestations and family history in PsSpA (n=127), AS (n=157) and pPsA (n=118) cases
| PsSpA | AS | pPsA | AS versus PsSpA |
pPsA versus PsSpA |
|||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | ORadj | 95% CI | p Value | ORadj | 95% CI | p Value | |
| Inflammatory axial symptoms | |||||||||
| Current | |||||||||
| Spine or buttocks | 65 (55) | 133 (85) | 54 (43) | 2.76 | 1.62 to 4.71 | <0.001* | 0.57 | 0.34 to 0.96 | 0.03* |
| Ever (past/current) | |||||||||
| Spine or buttocks | 88 (75) | 156 (99) | 77 (61) | 28.45 | 3.65 to 221.74 | 0.001* | 0.69 | 0.38 to 1.25 | 0.22* |
| Cervical | 71 (60) | 132 (84) | 54 (43) | 1.82 | 0.94 to 3.55 | 0.08* | 0.73 | 0.42 to 1.27 | 0.26* |
| Thoracic | 50 (42) | 114 (73) | 27 (21) | 2.20 | 1.23 to 3.92 | 0.01* | 0.48 | 0.26 to 0.88 | 0.02* |
| Lumbar | 70 (59) | 149 (95) | 58 (46) | 6.75 | 2.82 to 16.16 | <0.001* | 0.82 | 0.47 to 1.43 | 0.48* |
| Buttocks | 55 (47) | 132 (84) | 24 (19) | 3.19 | 1.67 to 6.07 | <0.001* | 0.38 | 0.20 to 0.71 | 0.003* |
| Extra-articular manifestations (ever) | |||||||||
| Dactylitis | 37 (31) | 8 (5) | 50 (39) | 0.18 | 0.07 to 0.42 | <0.001* | 1.09 | 0.62 to 1.93 | 0.76* |
| Enthesitis | 56 (47) | 58 (37) | 59 (46) | 0.70 | 0.43 to 1.14 | 0.15* | 0.93 | 0.56 to 1.55 | 0.79* |
| Chest wall pain | 52 (44) | 102 (65) | 34 (27) | 1.21 | 0.70 to 2.19 | 0.52* | 0.63 | 0.35 to 1.15 | 0.13* |
| Uveitis | 31 (26) | 84 (54) | 11 (9) | 1.44 | 0.79 to 2.62 | 0.24* | 0.52 | 0.22 to 1.22 | 0.13* |
| Inflammatory bowel disease | 13 (11) | 15 (10) | 2 (2) | 0.85 | 0.36 to 1.98 | 0.70* | 0.12 | 0.03 to 0.55 | 0.01* |
| Family history | |||||||||
| Spondyloarthritis | 25 (21) | 52 (33) | 16 (13) | 1.26 | 0.67 to 2.34 | 0.47† | 0.73 | 0.34 to 1.53 | 0.40† |
| Psoriasis | 58 (49) | 20 (13) | 56 (44) | 0.16 | 0.08 to 0.30 | <0.001 | 0.79 | 0.46 to 1.36 | 0.40 |
| Uveitis | 7 (6) | 37 (24) | 4 (3) | 2.27 | 0.94 to 5.51 | 0.07† | 1.84 | 0.42 to 7.99 | 0.42† |
| Inflammatory bowel disease | 9 (8) | 17 (11) | 11 (9) | 1.57 | 0.59 to 4.17 | 0.37 | 1.10 | 0.42 to 2.90 | 0.84 |
*Multivariable reverse-stepwise logistic regression model (adjusted for potential covariates, including: sex, age at assessment, disease duration at assessment, HLA-B*27 status, synthetic DMARD use ever, anti-TNF use ever, smoking ever and body mass index).
†Reverse-stepwise logistic regression model adjusted for HLA-B*27 status.
Anti-TNF, antitumour necrosis factor; AS, ankylosing spondylitis; DMARD, disease modifying antirheumatic drug; n, proportion; ORadj, adjusted OR; pPsA, peripheral psoriatic arthritis; PsSpA, psoriatic spondyloarthropathy.